Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat Administration of MST-188 in Sickle Cell Disease VOC
NCT02449616Phase 3Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Jun 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vepoloxamer in sickle cell disease (SCD), sponsored by Mast Therapeutics, Inc.. Started Jun 2015; status: completed.
02
Drugs
vepoloxamer
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02449616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02449616.